Some more thinks-in-ink, Qaigen have 3 current clinical trials involving Quantiferon-TB (2 recruiting). Given the comercialisation timeframe of 2020, I'm making an assumption that they will do parallel comparison test with QFT Access, . Its unclear if they are even going for FDA approval path at this stage - they would need 95% efficacy (remember Ellume Flu OTC tests ran into FDA headwinds with 85% efficacy). They appear to me that they are targeting non-FDA regions via WHO (similar to Atomo's OTC HIV tests). So JIMHO cents/test revenue - but lots of tests as counterbalance at 2☆3 year horizon. Asuming AnteoCoat integration.
ADO Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
